Healthcare | Corporate Finance Advisory

Immucor Board of Directors Re-Elected

  • Immucor, Inc. (NASDAQ: BLUD) is a leading supplier of diagnostic reagents and automated instrumentation to ensure the safety of blood transfusions
  • Kairos Partners, an 11.6% Immucor shareholder, launched a proxy contest to replace Immucor’s board of directors with an alternative slate of directors
  • TM Capital Corp. served as advisor to Immucor in its successful effort to defeat the dissident slate and re-elect Immucor’s existing directors

Client Testimonial